HK Stock Market Move | INSILICO(03696) rises nearly 8% as the AI pharmaceutical sector continues to heat up; the company's BD and PCC output hit record highs.

INSILICO(03696) rose nearly 8%, up 7.85% as of press time, at HK$59.75, with a turnover of HK$363 million. On the news front, according to the latest data, the total value of signed collaborations disclosed by INSILICO in 2026 has reached approximately US$7.3 billion, with cumulative outbound licensing deals totaling US$11 billion. In terms of AI-driven R&D, INSILICO nominated 9 preclinical candidate compounds (PCCs) in the first 9 months of this year, setting a new historical record for the company's annual pipeline output. CLSA believes that the company's business development momentum remains strong, and the China Phase III clinical trial of its AI-driven innovative drug candidate Rentosertib is the next major clinical validation point. It is worth noting that the recent intensive ramp-up by multinational giants in AI pharmaceuticals has further heated up the sector. Roche disclosed during an investor event that it will advance the construction of its own artificial intelligence laboratory to accelerate new drug discovery. Previously, Novo Nordisk and Eli Lilly also successively disclosed progress in wet lab collaborations. Citi pointed out that INSILICO remains the bank's top pick in the AI drug discovery (AIDD) sub-sector.